乳癌：新型療法、未滿足的需求和TPP洞察報告，2026年

Breast Cancer - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

出版日期: 2026年01月07日 | 出版商:

Thelansis Knowledge Partners | 英文 54 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

市場概覽

西班牙乳癌市場預計將從約19億美元成長到36億美元，反映出強勁的市場擴張。
市場成長受以下因素支撐：
CDK4/6抑制劑和HER2標靶抗體偶聯藥物的應用日益廣泛
免疫療法和精準醫療方法的應用日益廣泛
市場擴張的驅動力是高附加價值的標靶治療、分階段的治療方案引入以及更長的治療週期。
未來的成長取決於下一代抗體藥物偶聯物、新型內分泌療法和基於生物標記的治療策略的擴展。

新型乳癌治療方法及對TPP的深入理解

Thelansis 的《乳癌新興治療方法、未滿足的需求和 TPP 洞察報告 - 2026》對該適應症的關鍵新興治療方法和主要藥物發現機會進行了全面分析，包括新興的競爭格局、未滿足的需求、目標產品概況 (TPP)、試驗設計和關鍵意見領袖 (KOL) 的見解。

乳癌概述

乳癌是全球女性最常見的惡性腫瘤，大致可分為三種亞型：荷爾蒙受體陽性/HER2陰性乳癌（HR+/HER2-）、HER2陽性乳癌和三陰性乳癌（TNBC）。每種亞型都具有獨特的生物學特徵和治療方法。此疾病的特徵是乳房組織細胞不受控制地增殖，其進展受荷爾蒙、遺傳和分子因素的影響。隨著疾病的進展，癌細胞可轉移至遠端器官，顯著影響患者的存活率和生活品質。

治療方案包括手術、放射線治療、化療、內分泌治療、分子標靶治療和免疫治療，取決於疾病分期和分子亞型。對於荷爾蒙受體陽性（HR+）病例，內分泌治療合併 CDK4/6 抑制劑仍是標準治療方案；而對於 HER2 陽性和 HER2 低表達病例，HER2標靶治療和抗體藥物複合體（ADC），例如曲妥珠單抗和 T-DM1，已顯著改善了治療效果。儘管隨著免疫療法（例如沙妥珠單抗和 ADC）的引入，三陰性乳癌（TNBC）的治療已取得進展，但化療在控制疾病進行性方面仍然發揮著重要作用。

治療格局正日益向精準醫療轉變，尤其體現在基因組分析、基於生物標記的治療選擇以及針對BRCA突變患者的PARP抑制劑的應用。儘管治療方法取得了進展，但治療抗藥性、轉移復發、安全性問題以及獲得先進療法的機會不均等挑戰仍然影響著疾病的最佳管理。未來的創新重點在於下一代抗體藥物偶聯物（ADC）、聯合標標靶治療以及旨在提高生存率和改善患者長期預後的個人化治療策略。

主要亮點

據預測，到 2035 年，法國新增乳癌病例數將從約 62,000 例增加到近 73,000 例，反映出該疾病的負擔日益加重。
在所有主要市場中，HR陽性/HER2陰性乳癌患者群體仍然最大。
針對 HER2 的抗體藥物偶聯物 (ADC) 正在顯著改變 HER2 陽性和 HER2 低表達疾病的治療模式。
儘管近年來免疫療法和基於抗體藥物偶聯物（ADC）的治療方法取得了進展，但三陰性乳癌（TNBC）領域仍存在大量未滿足的需求。
基因組分析和基於生物標記的治療方法選擇的日益普及，正在加速精準腫瘤學方法的進步。

基於對醫生和關鍵意見領袖（KOL）的調查得出的結論：

透過對關鍵意見領袖 (KOL) 的訪談，我們獲得了更多見解，從而進一步完善了調查結果。
調查問卷將根據客戶的要求進行客製化。

交付成果格式：

PowerPoint簡報
MS Excel

主要問題

詳細的競爭格局趨勢
管道分析
符合新興治療方法的患者
主要企業
主要作用機制
發布日期等的預測
臨床試驗趨勢分析
目標患者群
試驗終點
測試設計
受試者招募標準等。
未滿足的需求和機遇
目前主要治療方法的有效性
未滿足需求的關鍵領域
估算主要未滿足需求的市場規模
目標產品概況
屬性和級別
醫生開立的處方
預期患者佔有率
關鍵KOL洞察對領先新興治療方法的見解
意識
預期用途/處理線
對主要未滿足需求的滿意度
KOL評論

目標國家

G8
- 美國
- EU5
  - 法國
  - 德國
  - 義大利
  - 西班牙
  - 英國
- 日本
- 中國

大公司

Pfizer
Merck Sharp &Dohme LLC
Boundless Bio, Inc.
Sichuan Baili Pharmaceutical Co., Ltd.
MedSIR
ExpreS2ion Biotechnologies
Stemline Therapeutics, Inc.
Genentech, Inc.
Cellectar Biosciences, Inc.
SURGE Therapeutics
Eli Lilly and Company
Celcuity Inc
Arvinas Estrogen Receptor, Inc.
Tolmar Inc.
Jazz Pharmaceuticals
Hoffmann-La Roche
Regor Pharmaceuticals Inc.
AstraZeneca
Eisai Inc.
SCRI Development Innovations, LLC
Beijing Wehand-Bio Pharmaceutical Co., Ltd.
Shandong Suncadia Medicine Co., Ltd.
InventisBio Co., Ltd
Daiichi Sankyo
TransThera Sciences（Nanjing）, Inc.
Atridia Pty Ltd.
Novartis Pharmaceuticals
Olema Pharmaceuticals, Inc.
Greenwich LifeSciences, Inc.
Incyclix Bio

Thelansis's "Breast Cancer Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Breast Cancer Overview

Breast cancer is the most commonly diagnosed malignancy among women worldwide and is broadly classified into HR+/HER2-negative, HER2-positive, and triple-negative breast cancer (TNBC) subtypes, each associated with distinct biological characteristics and treatment approaches. The disease is characterized by uncontrolled growth of breast tissue cells, with progression influenced by hormonal, genetic, and molecular factors. Advanced disease can metastasize to distant organs, significantly impacting survival and quality of life.

Management involves a multimodal approach including surgery, radiation therapy, chemotherapy, endocrine therapy, targeted therapy, and immunotherapy depending on disease stage and molecular subtype. In HR+ disease, endocrine therapy combined with CDK4/6 inhibitors remains the standard of care, while HER2-targeted therapies and antibody-drug conjugates (ADCs) such as trastuzumab deruxtecan and T-DM1 have transformed outcomes in HER2-positive and HER2-low disease. TNBC treatment has evolved with the introduction of immunotherapy and ADCs such as sacituzumab govitecan, although chemotherapy continues to play a major role in aggressive disease management.

The treatment landscape is increasingly shifting toward precision medicine through genomic profiling and biomarker-driven therapy selection, including PARP inhibitors for BRCA-mutated patients. Despite therapeutic advancements, challenges such as treatment resistance, metastatic recurrence, safety concerns, and unequal access to advanced therapies continue to impact optimal disease management. Future innovation is focused on next-generation ADCs, combination targeted therapies, and personalized treatment strategies aimed at improving survival and long-term patient outcomes.

Key Highlights

In France, incident breast cancer cases are projected to increase from approximately 62,000 to nearly 73,000 by 2035, reflecting a rising disease burden.
HR+/HER2-negative breast cancer continues to account for the largest patient population across major markets.
HER2-targeted ADCs are significantly reshaping treatment paradigms in HER2-positive and HER2-low disease.
TNBC remains an area of high unmet need despite recent advances in immunotherapy and ADC-based therapies.
Increasing adoption of genomic profiling and biomarker-driven treatment selection is accelerating precision oncology approaches.

Market Overview

The Spain breast cancer market is projected to grow from approximately $1.9B to $3.6B, reflecting strong market expansion.
Market growth is supported by:
Increased uptake of CDK4/6 inhibitors and HER2-targeted ADCs
Rising adoption of immunotherapy and precision medicine approaches
Market value growth is driven by premium targeted therapies, sequential treatment use, and longer treatment duration.
Future growth will depend on next-generation ADCs, novel endocrine therapies, and expanded biomarker-guided treatment strategies.